Skip to content
Menu

Celcuity Inc. CELC

Full chart Compare
Set alert

Price alert · CELC

All alert types
53.35 USD -2.96 (-5.26%)

Regular-session close

53.35 0.00 0.00%

After hours · Nov 20, 4:52 PM ET

53.20 Day range 57.00
53.35 52-week range 144.98
YTD
-46.51%
1 year
-43.24%

5D -10.20 (-15.99%)

5560MonTueWedThuFri53.57
Market cap
2.61B
EPS (ttm)
-4.72
Shares out
48.93M
Forward P/E
-10658.00
YTD return
-46.51%
1-year return
-43.24%
50-day average
69.79
200-day average
97.40
Enterprise value
2.88B
Free cash flow
-182.41M
Volume
636.53K
Avg volume
1.25M
Open
55.02
Previous close
56.31
Day's range
53.20 – 57.00
52-week range
53.35 – 144.98
Beta
0.13
Analysts
Strong Buy
Price target
150.85 (+182.7%)
Earnings date
Mar 24, 2027

Key statistics

Total cash
642.70M
Total debt
755.07M
Return on equity
-1192.88%
Short % of float
31.59%

Fundamental scorecard

1 of 25 checks passed on CELC’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CELC Revenue — quarterly 0
CELC Net income — quarterly -73.34M
CELC EPS — quarterly -1.33

Earnings

CELC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 24, 2027Mar 30, 2027-1.34———
Nov 5, 2026Sep 30, 2026-1.51-1.21+0.30+19.87%
Aug 13, 2026Jun 30, 2026-1.16-1.44-0.28-24.14%
May 14, 2026Mar 31, 2026-1.04-0.97+0.07+6.73%
Mar 25, 2026Dec 31, 2025-1.06-0.97+0.09+8.49%
Nov 12, 2025Sep 30, 2025-1.02-0.92+0.10+9.80%

Upgrades / downgrades

CELC analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026HC Wainwright & Co.mainBuyBuy
Nov 6, 2026GuggenheimmainBuyBuy
Nov 2, 2026GuggenheimmainBuyBuy
Oct 22, 2026Cantor Fitzgeraldinit—Overweight
Oct 21, 2026TD CowenreitBuyBuy
Sep 30, 2026NeedhammainBuyBuy

About Celcuity Inc.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
celcuity.com

News

Your note

Sign in to keep a note on CELC — it syncs with the Stock Master app.

Insider holders

CELC insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS L.P.UnknownSaleJul 13, 20260
BULLER RICHARD EDirectorStock Award(Grant)Jun 4, 20269,319
DALVEY DAVID FDirectorStock Award(Grant)Jun 4, 202666,530
FURCHT LEO M.D.DirectorStock Award(Grant)Jun 4, 202612,530
HAHNE VICKYChief Financial OfficerStock Award(Grant)Aug 13, 202637,808
LAING LANCE G PH.D.Officer and DirectorStock Award(Grant)Aug 13, 20261,271,000

Institution ownership

CELC institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP9.80%4,815,792256.63MSep 29, 2026
RTW Investments LP6.73%3,304,903176.12MSep 29, 2026
Blackrock Inc.6.47%3,177,631169.34MSep 29, 2026
Perceptive Advisors Llc6.47%3,179,794169.45MSep 29, 2026
Deerfield Management Company, L.P4.88%2,397,664127.77MSep 29, 2026
State Street Corporation4.19%2,056,176109.57MSep 29, 2026

Fund ownership

CELC fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.84%1,394,05674.29MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.44%1,197,16963.80MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.03%996,07053.08MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio0.98%479,20325.54MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund0.94%461,83624.61MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.89%436,21223.25MJun 29, 2026